首页 > 市场调查报告书 > 製药

癌症

到 2030 年北美乳癌治疗市场预测 - 区域分析 - 按药物治疗、乳癌类型和配销通路

市场调查报告书

商品编码

1481920

到 2030 年北美乳癌治疗市场预测 - 区域分析 - 按药物治疗、乳癌类型和配销通路

North America Breast Cancer Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Therapy, Breast Cancer Type, and Distribution Channel

出版日期: 2024年03月04日 | 出版商:

The Insight Partners | 英文 94 Pages | 订单完成后即时交付

价格

简介目录图表

2022年北美乳癌治疗市值为133.4687亿美元，预计到2030年将达到270.1492亿美元；预计 2022 年至 2030 年复合年增长率为 9.2%。

个人化医疗的增加使用推动了北美乳癌治疗市场

个人化医疗涉及根据个别患者的基因组成等因素制定治疗计划。这种方法考虑到每位患者癌症的独特特征，因此可以实现高度针对性和有效的治疗。基因组学和分子诊断的进步使个人化医疗成为乳癌治疗的可行选择。医疗保健提供者可以透过在分子层面分析患者的肿瘤来识别驱动癌症生长的特定基因突变或生物标记。然后可以使用这些资讯来选择最合适的治疗方案，例如可能对特定患者最有效的标靶疗法或免疫疗法。在乳癌治疗中使用个人化医疗有可能显着改善患者的治疗效果。例如，2022 年2 月，NIH 研究人员开发了一种个人化乳癌治疗方法，这是一种实验性的免疫疗法，利用患者的抗肿瘤免疫细胞来治疗转移性乳癌患者，从而推进个人化医疗。

透过为个别患者提供量身定制的治疗，医疗保健提供者可以增加成功结果的可能性并降低不必要的副作用的风险。除了改善患者的治疗效果外，个人化医疗还可以带来经济效益。透过选择更有可能有效的治疗方法，医疗保健提供者可以减少与无效治疗相关的医疗费用，并避免不必要的费用。随着基因组学和分子诊断的进步，个人化医疗可能在未来几年变得越来越容易获得并融入标准治疗方案。因此，个人化医疗的日益使用预计将为北美乳癌治疗市场带来新的成长趋势。

北美乳癌治疗市场概况

北美的乳癌治疗市场分为美国、加拿大和墨西哥；美国在该地区占有最大的市场份额。市场成长主要归因于该地区，由于乳癌盛行率上升以及开发新疗法的研发投资增加等因素，预计该地区将持续成长。此外，越来越多的市场参与者正在扩大其在北美国家的地理足迹。

医疗技术和研究的进步催生了突破性治疗方法，可以改善患者的治疗效果。辉瑞（Pfizer）、诺华（Novartis）、罗氏（Roche）、阿斯特捷利康（AstraZeneca）和礼来（Eli Lilly）等几家大型製药公司主导了美国乳癌治疗市场。这些企业在研发方面进行了大量投资，以向市场推出新型和增强型药物。政府制定的法规和政策也会影响市场。用于乳癌治疗的新药物和疗法已获得美国食品药物管理局 (FDA) 政府机构的批准。未来几年，乳癌的治疗市场预计将进一步扩大。

北美乳癌治疗市场收入及 2030 年预测（百万美元）

北美乳癌治疗市场细分

北美乳癌治疗市场根据药物治疗、乳癌类型和配销通路进行细分。

根据药物治疗，北美乳癌治疗市场分为标靶药物治疗、荷尔蒙药物治疗、化疗和免疫治疗/生物治疗。 2022年，标靶药物治疗细分市场将占据更大份额。此外，荷尔蒙药物治疗部分分为选择性雌激素受体调节剂、芳香酶抑制剂和选择性雌激素受体下调剂。

就乳癌类型而言，北美乳癌治疗市场分为荷尔蒙受体乳癌、HER2+乳癌和三阴性乳癌。 2022 年，荷尔蒙受体细分市场将占据更大份额。

依配销通路，北美乳癌治疗市场分为医院药局、药局和零售药局、网路药局。 2022年，医院药局部门将占据更大的份额。

按国家/地区划分，北美乳癌治疗市场分为美国、加拿大和墨西哥。 2022 年，美国将主导北美乳癌治疗市场。

礼来公司、卫材有限公司、诺华公司、阿斯特捷利康公司、辉瑞公司、吉利德科学公司、默克公司、基因泰克公司、梯瓦製药工业有限公司和安进公司是北美乳房领域的一些领先公司癌症治疗市场。

Personalized medicine involves tailoring treatment plans to individual patients on the basis of their genetic makeup, among other factors. This approach allows for highly targeted and effective treatments, as it considers the unique characteristics of each patients cancer. Advancements in genomics and molecular diagnostics have made personalized medicine a viable option in breast cancer treatment. Healthcare providers can identify specific genetic mutations or biomarkers driving the cancers growth by analyzing a patients tumor at a molecular level. This information can then be used to select the most appropriate treatment options, such as targeted therapies or immunotherapies, that are likely to be the most effective for that particular patient. The use of personalized medicine in breast cancer therapeutics has the potential to significantly improve patient outcomes. For instance, in February 2022, NIH researchers developed a personalized breast cancer therapy approach, an experimental form of immunotherapy that uses a patients tumor-fighting immune cells to treat those with metastatic breast cancer, advancing personalized medicine.

By providing tailored treatments to individual patients, healthcare providers can increase the likelihood of successful outcomes and reduce the risk of unnecessary side effects. In addition to improving patient outcomes, personalized medicine also offers economic benefits. By selecting treatments that are more likely to be effective, healthcare providers can reduce healthcare costs associated with ineffective treatments and avoid unnecessary expenses. As advancements in genomics and molecular diagnostics progress, personalized medicine is likely to become increasingly accessible and integrated into standard treatment protocols in the coming years. Therefore, the increasing use of personalized medicine is anticipated to bring new growth trends in the North America breast cancer therapeutics market.

North America Breast Cancer Therapeutics Market Overview

The breast cancer therapeutics market in North America is segmented into the US, Canada, and Mexico; the US holds the largest market share in this region. The market growth is mainly attributed to the region, which is expected to witness consistent growth owing to factors such as the rising prevalence of breast cancer and rising R&D investments for developing novel treatments. In addition, a growing number of market players are expanding their geographical footprint in North American countries.

Improvements in medical technology and research have sparked the creation of ground-breaking treatments that can enhance patient outcomes. Several large pharmaceutical companies, including Pfizer, Novartis, Roche, AstraZeneca, and Eli Lilly, dominate the therapeutic market for breast cancer in the US. These businesses make significant investments in research and development to introduce novel and enhanced medicines to the market. Regulations and policies put in place by the government also affect the market. New medications and therapies for breast cancer treatment are approved by the government agencies of the Food and Drug Administration (FDA). In the upcoming years, the therapeutic market for breast cancer is anticipated to expand further.

North America Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

North America Breast Cancer Therapeutics Market Segmentation

The North America breast cancer therapeutics market is segmented based on drug therapy, breast cancer type, and distribution channel.

Based on drug therapy, the North America breast cancer therapeutics market is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment is further subsegmented into abemaciclib, ado-trastuzumab emtansine, palbociclib, trastuzumab, and other target drug therapy. Additionally, the hormonal drug therapy segment is categorized into selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor downregulators.

In terms of breast cancer type, the North America breast cancer therapeutics market is segmented into hormone receptor, HER2+, and triple-negative breast cancer. The hormone receptor segment held a larger share in 2022.

By distribution channel, the North America breast cancer therapeutics market is segmented into hospital pharmacies, drug store and retail pharmacies, and online pharmacies. The hospital pharmacies segment held a larger share in 2022.

Based on country, the North America breast cancer therapeutics market is categorized into US, Canada, and Mexico. The US dominated the North America breast cancer therapeutics market in 2022.

Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Genentech Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc are some of the leading companies operating in the North America breast cancer therapeutics market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Breast Cancer Therapeutics Market - Key Industry Dynamics

4.1 Key Market Drivers
- 4.1.1 Growing Burden of Breast Cancer
- 4.1.2 Launch of Several Diagnostics and Screening Programs
4.2 Key Market Restraints
- 4.2.1 High Cost of Diagnosis and Treatment
4.3 Key Market Opportunities
- 4.3.1 Increased Support from Government and Private Organizations
4.4 Key Future Trends
- 4.4.1 Increasing Use of Personalized Medicine
4.5 Impact Analysis:

5. Breast Cancer Therapeutics Market - North America Market Analysis

5.1 North America Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030

6. North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Drug Therapy

6.1 Overview
6.2 North America Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
6.3 Targeted Drug Therapy
- 6.3.1 Overview
- 6.3.2 Targeted Drug Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.3.2.1 North America Breast Cancer Therapeutics Market, by Targeted Drug Therapy, 2020-2030 (US$ Million)
6.4 Hormonal Drug Therapy
- 6.4.1 Overview
- 6.4.2 Hormonal Drug Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.4.2.1 North America Breast Cancer Therapeutics Market, by Hormonal Drug Therapy, 2020-2030 (US$ Million)
6.5 Chemotherapy
- 6.5.1 Overview
- 6.5.2 Chemotherapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.6 Immunotherapy/ Biological Therapy
- 6.6.1 Overview
- 6.6.2 Immunotherapy/ Biological Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Breast Cancer Type

7.1 Overview
7.2 North America Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
7.3 Hormone Receptor
- 7.3.1 Overview
- 7.3.2 Hormone Receptor: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 HER2+ (human epidermal growth factor receptor 2)
- 7.4.1 Overview
- 7.4.2 HER2+: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Triple-Negative Breast Cancer
- 7.5.1 Overview
- 7.5.2 Triple-Negative Breast Cancer: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Distribution Channel

8.1 Overview
8.2 North America Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
8.3 Hospital Pharmacies
- 8.3.1 Overview
- 8.3.2 Hospital Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Drug Store and Retail Pharmacies
- 8.4.1 Overview
- 8.4.2 Drug Store and Retail Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
- 8.5.1 Overview
- 8.5.2 Online Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Breast Cancer Therapeutics Market - Regional Analysis

9.1 North America Breast Cancer Therapeutics Market, Revenue and Forecast To 2030
- 9.1.1 Overview
- 9.1.2 North America Breast Cancer Therapeutics Market, Breakdown, by Country, Revenue (2022) (US$ Million)
- 9.1.3 North America Breast Cancer Therapeutics Market, by Country
  - 9.1.3.1 US
    - 9.1.3.1.1 US Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.1.2 US: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.1.2.1 US: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.1.2.2 US: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.1.3 US: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
    - 9.1.3.1.4 US: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.3.2 Canada
    - 9.1.3.2.1 Canada Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.2.2 Canada: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.2.2.1 Canada: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.2.2.2 Canada: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.2.3 Canada: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
    - 9.1.3.2.4 Canada: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.3.3 Mexico
    - 9.1.3.3.1 Mexico Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.3.2 Mexico: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.3.2.1 Mexico: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.3.2.2 Mexico: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.3.3 Mexico: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
    - 9.1.3.3.4 Mexico: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)

10. Breast Cancer Therapeutics Market-Industry Landscape

10.1 Overview
10.2 Growth Strategies in Breast Cancer Therapeutics Market
10.3 Organic Growth Strategies
- 10.3.1 Overview
10.4 Inorganic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Eli Lilly and Co
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Eisai Co Ltd
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Novartis AG
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 AstraZeneca Plc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Pfizer Inc
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Gilead Sciences Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Merck & Co Inc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Amgen Inc
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 Amgen Inc
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms

简介目录图表

List Of Tables

Table 1. North America Breast Cancer Therapeutics Market Segmentation
Table 2. North America Breast Cancer Therapeutics Market, by Targeted Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 3. North America Breast Cancer Therapeutics Market, by Hormonal Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 4. US Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 5. US Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 6. US Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 7. US Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 8. US Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 9. Canada Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 10. Canada Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 11. Canada Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 12. Canada Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 13. Canada Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 14. Mexico Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 15. Mexico Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 16. Mexico Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 17. Mexico Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 18. Mexico Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 19. Recent Organic Growth Strategies in Breast Cancer Therapeutics Market
Table 20. Recent Inorganic Growth Strategies in the Breast Cancer Therapeutics Market
Table 21. Glossary of Terms, Breast Cancer Therapeutics Market

List Of Figures

Figure 1. North America Breast Cancer Therapeutics Market Segmentation, By Country
Figure 2. North America Breast Cancer Therapeutics Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030
Figure 5. North America Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
Figure 6. Targeted Drug Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Hormonal Drug Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Chemotherapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Immunotherapy/ Biological Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. North America Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
Figure 11. Hormone Receptor: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. HER2+: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Triple-Negative Breast Cancer: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. North America Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
Figure 15. Hospital Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Drug Store and Retail Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Online Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. North America Breast Cancer Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 19. North America Breast Cancer Therapeutics Market, By Key Countries, 2022 and 2030 (%)
Figure 20. US Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Canada Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Mexico Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Growth Strategies in Breast Cancer Therapeutics Market